Spots Global Cancer Trial Database for SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

Official Title: Predictive Factors for the Benefit of Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

Study ID: NCT03604211

Conditions

Prostate Cancer Recurrent

Prostate Cancer

Lymph Node Metastases

Interventions

Cyberknife Radiation Therapy

Study Description

Brief Summary: Single-institution retrospective analysis for predictive factors of prostate cancer patients presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Detailed Description: Single-institution retrospective analysis of consecutive prostate cancer patients after definitive primary treatment, without local recurrence, presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015. Endpoints of interest are biochemical response rate (defined as a reduction by at least 10% of the initial PSA value), time to biochemical recurrence (TBR) (defined as the time interval from SBRT until second PSA rise), and time interval between SBRT and ADT start. Univariate analysis is used to identify prognostic factors.